LEXX — Lexaria Bioscience Income Statement
0.000.00%
Last trade - 00:00- $23.70m
- $16.78m
- $0.46m
Annual income statement for Lexaria Bioscience, fiscal year end - August 31st, USD millions except per share, conversion factor applied.
R2020 August 31st | 2021 August 31st | 2022 August 31st | 2023 August 31st | 2024 August 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.315 | 0.723 | 0.255 | 0.226 | 0.464 |
| Cost of Revenue | |||||
| Gross Profit | 0.215 | 0.547 | 0.184 | 0.195 | 0.459 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 4.46 | 6.41 | 7.64 | 6.94 | 6.27 |
| Operating Profit | -4.15 | -5.69 | -7.38 | -6.71 | -5.81 |
| Net Income Before Taxes | -4.15 | -5.69 | -7.38 | -6.71 | -5.81 |
| Net Income After Taxes | -4.15 | -5.69 | -7.38 | -6.71 | -5.81 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -3.93 | -4.03 | -7.27 | -6.66 | -5.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.93 | -4.03 | -7.27 | -6.66 | -5.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.44 | -1.26 | -1.23 | -0.992 | -0.463 |